On December 20, WuXi Biologics announced that it had reached a research service cooperation agreement with Hangzhou Duoxi Biotechnology Co., Ltd. and Aadi Bioscience to support Aadi in developing three new-generation antibody-drug conjugates (ADCs) in the preclinical stage. According to the terms of the agreement, Aadi will pay WuXi Biologics and Duoxi Bioscience a down payment of US$44 million, a development milestone payment of up to US$265 million, a commercial milestone payment of US$540 million, and a single-digit sales commission.